Kim, RichardCoppola, DomenicoWang, EmilieChang, Young DooKim, YuhreeAnaya, DanielKim, Dae Won2018-06-272018Kim, Richard, Domenico Coppola, Emilie Wang, Young Doo Chang, Yuhree Kim, Daniel Anaya, and Dae Won Kim. 2018. “Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma.” Oncotarget 9 (34): 23366-23372. doi:10.18632/oncotarget.25163. http://dx.doi.org/10.18632/oncotarget.25163.http://nrs.harvard.edu/urn-3:HUL.InstRepos:37160274Cholangiocarcinoma is a malignancy arising from the biliary tract epithelial cells with poor prognosis. Tumor infiltrating lymphocytes (TIL)s and programmed cell death receptor ligand 1 (PD-L1) have a prognostic impact in various solid tumors. We aimed to investigate TILs and PD-L1 expression and their clinical relevance in cholangiocarcinoma. Tumor samples from 44 patients with resected and histologically verified extrahepatic cholangiocarcinoma were evaluated for CD8, CD45RO and PD-L1 expression, and their correlations with clinicopathological data and survival data were analyzed. Total 44 extrahepatic cholangiocarcinoma tissues were evaluated. CD8+ tumor infiltrating lymphocytes (TIL)s were observed in 30 (68%) tumors. Among them, 14 had CD8+CD45RO+ TILs. PD-L1 was expressed on cancer cells in 10 (22.7%) tumors in 34 evaluable extrahepatic cholangiocarciniomas. The presence of CD8+ TILs or CD8+CD45RO+ TILs was not associated with clinical staging or tumor differentiation. Extrahepatic cholangiocarcinoma with CD8+CD45RO+ TILs had longer overall survival (OS) on univariate (P = 0.013) and multivariate (P = 0.012) analysis. Neither CD8+TIL nor PD-L1 expression on cancer cells correlated significantly with OS. These results add to the understanding of the clinical features associated with CD8 TILs and PD-L1 expression in extrahepatic cholangiocarcinoma, and they support the potential rationale of using PD-1 blockade immunotherapy in cholangiocarcinoma.en-UScholangiocarcinomatumor infiltrating lymphocytestumor microenvironmentPD-L1Journal Article2018-06-2710.18632/oncotarget.25163